Carboplatin

Human OC cell lines (A2780, HO8910, and OVCAR3) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All human cell lines have been authenticated using STR profiling. Cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin (HyClone); the incubation was carried out at 37 °C in a 5% CO₂ atmosphere. HLF knockdown; YAP1 knockdown; control lentiviruses (designated as shHLF, shYAP1, and shCtrl); and lentiviruses expressing Flag-HLF, Flag-YAP1, or Flag (designated as HLF, YAP1, and Control) were obtained from Obio Technology Co. (Shanghai, China). The miR-520e sponge and mimic viruses were purchased from GenePharma (Shanghai, China). siRNA sequences are listed in Supplementary Table S7.
In order to establish carboplatin-resistant cell lines, A2780, HO8910, and OVCAR3 cells were incubated with carboplatin (Selleck, S1215) at a concentration just below their IC₅₀; the concentration of carboplatin was gradually increased by 0.2 μM/L per week for 6–7 months. Three carboplatin-resistant cell lines, A2780CR, HO8910CR, and OVCAR3CR, were obtained. These carboplatin-resistant cell lines were maintained by continuous culture in the presence of carboplatin.

Drugs including cisplatin, carboplatin, and paclitaxel were purchased from Selleckchem (Houston, TX, USA). For the generation of CR NSCLC cell lines, the starting concentration of cisplatin in A549 cell cultures was 1 µM, while the final concentration reached 12 µM within 3 weeks. In the PC9 cell cultures starting concentration of cisplatin was 0.67 µM that was increased to 4.67 µM within 3 weeks. carboplatin and paclitaxel treatment were applied for 24 h in 100 µM and in 0.002 µM concentrations, respectively.